Browse Category

Financial News News 13 December 2025 - 14 December 2025

Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Updated: Friday, December 12, 2025 (U.S. market close) Milestone Pharmaceuticals Inc. (NASDAQ: MIST) closed out the week in the spotlight after the company announced U.S. FDA approval of CARDAMYST™ (etripamil)—positioning Milestone to transition from a development-stage biotech to a commercial-stage
McKesson Stock Forecast: MCK Rebounds to $813.80 After Barclays’ Overweight Call — What to Watch Next Week (Updated Dec. 12, 2025)

McKesson Stock Forecast: MCK Rebounds to $813.80 After Barclays’ Overweight Call — What to Watch Next Week (Updated Dec. 12, 2025)

Updated: Friday, December 12, 2025 (U.S. market close) McKesson Corporation (NYSE: MCK) ended the week on a steadier footing after an early-week dip, closing Friday at $813.80. The stock is still down roughly 9% from its late-November 52‑week high ($895.58
HCA Stock Outlook: HCA Healthcare (NYSE: HCA) Ends the Week Near $485 After a Volatile Swing — Latest News, Forecasts, and the Week Ahead (Updated Dec. 12, 2025)

HCA Stock Outlook: HCA Healthcare (NYSE: HCA) Ends the Week Near $485 After a Volatile Swing — Latest News, Forecasts, and the Week Ahead (Updated Dec. 12, 2025)

Updated: December 12, 2025 (U.S. market close)HCA Healthcare, Inc. (NYSE: HCA) closed Friday at $484.77, finishing the week essentially flat—but not quiet. A sharp midweek drop and quick rebound put policy risk, reimbursement headlines, and year-end positioning back in the
Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Updated: Dec. 12, 2025 (U.S. market close) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) finished Friday at $452.04, extending a late-week rebound after a choppy start to the week. The stock’s intraday range on Friday stretched from $442.94 to $455.99 on volume
1 187 188 189 190 191 317
Go toTop